Correvio Pharma Corp. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2018. For the quarter, the company reported product and royalty revenues of $6,984,000 against $5,970,000 for the same period a year ago. The increase in revenue was primarily attributable to the commercial rollout of Xydalba(TM) and sales of Zevtera(R) /Mabelio(R), which Correvio acquired from Basilea Pharmaceutica International Ltd. in September 2017. Operating loss was $5,303,000 against $4,838,000 for the same period a year ago. Loss before income taxes was $7,066,000 against $6,549,000 for the same period a year ago. Net loss was $7,105,000 or $0.20 per basic and diluted share against $6,623,000 or $0.20 per basic and diluted share for the same period a year ago. Net cash used in operating was $7,460,000 against $5,276,000 for the same period a year ago. Purchase of property and equipment was $15,000 for the third quarter of 2018. Purchase of intangible assets was $18,000 against $5,206,000 for the same period a year ago. For the nine months, the company reported product and royalty revenues of $19,657,000 against $16,828,000 for the same period a year ago. Operating loss was $22,550,000 against $16,715,000 for the same period a year ago. Loss before income taxes was $9,997,000 against $21,363,000 for the same period a year ago. Net loss was $10,137,000 or $0.29 per basic and diluted share against $21,468,000 or $0.66 per basic and diluted share for the same period a year ago. Net cash used in operating was $21,397,000 against $19,186,000 for the same period a year ago. Purchase of property and equipment was $281,000 against $5,000 for the same period a year ago. Purchase of intangible assets was $4,682,000 against $5,219,000 for the same period a year ago.